BridgeBio Pharma (BBIO) Stock Forecast & Price Target
Score
BridgeBio Pharma, Inc. price target
| BBIO | |
|---|---|
| Low | $87.00 |
| Average | $112.83 |
| High | $156.00 |
| Upside vs current price | +47.5% |
The average target of $112.83 is +47.5% versus the current BBIO price of $76.52.
BridgeBio Pharma, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 14 |
| Hold | 3 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
22 analysts cover BBIO.
BridgeBio Pharma, Inc. EPS and revenue estimates
Published annual figures for BBIO on this page are 2026 EPS $-2.68, 2027 EPS $-0.81. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-2.68 | $1.09B |
| 2027 | $-0.81 | $1.66B |
Is BridgeBio Pharma, Inc. a buy or sell?
Of the 22 analysts covering BridgeBio Pharma, Inc., 19 rate it a buy (5 strong buy and 14 buy), 3 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The BBIO consensus label is Buy, beside 19 buy-side ratings and 0 sell-side ratings.
The average target of $112.83 implies +47.5% versus the current price of $76.52.
The BBIO rating block is 22 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the BridgeBio Pharma, Inc. forecast
A wide spread is the story on BBIO. Targets run from $87.00 to $156.00, with $112.83 as the average.
The gap from the $76.52 price to the BBIO average is +47.5%.
The BBIO rating mix is lopsided rather than split: 19 of 22 analysts are on the buy side, 3 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Month by month, the BBIO average target is higher ($113.75) than the quarterly average ($109.27).
the BridgeBio Pharma, Inc. is followed by 22 analysts, so the range matters more than any one target.
BridgeBio Pharma, Inc. forecast questions
What is the BBIO price target?
The published range for BBIO is $87.00 to $156.00, with an average of $112.83. That average is +47.5% versus the current price of $76.52.
Is BridgeBio Pharma, Inc. a buy or sell?
Of the 22 analysts covering BridgeBio Pharma, Inc., 19 rate it a buy, 3 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving BBIO at 19 buy ratings, 3 holds, and 0 sells.
What is the EPS estimate for BridgeBio Pharma, Inc.?
Analyst EPS estimates for BridgeBio Pharma, Inc.: 2026 $-2.68, 2027 $-0.81.
What is the revenue estimate for BridgeBio Pharma, Inc.?
Analyst revenue estimates for BridgeBio Pharma, Inc.: 2026 $1.09B, 2027 $1.66B.
How many analysts cover BBIO?
22 analysts cover BBIO. Their consensus on BBIO is Buy, across those 22.